Goldman Sachs analysts added Novonesis (NVZMY) to the firm’s European Conviction List as part of its monthly update. The firm believes there is “significant discovery value” post the merger of Novozymes and Chr Hansen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: